Путешествия по Европе Голосов: 2 Адрес блога: http://sempreprimo.blogspot.com/ Добавлен: 2008-08-17 13:20:58 блограйдером avanti

Abu Dhabi rents set to drop on new supplies

2012-02-22 12:11:21 (читать в оригинале)

With supply expected to outstrip demand over the next 12 months, rental rates in Abu Dhabi will drop further this year as the emirate gears up for a growth of five per cent in 2012, real-estate consultant CB Richard Ellis said.

---

Chile sees $1b potential for food exports to UAE

2012-02-22 12:09:20 (читать в оригинале)

Chile seeks to promote trade and investment relations with the UAE due to wide scope of cooperation in various sectors including the food, beverages and pharmaceutical sectors, its top official said.

---

Cable cut to hit Net users in the UAE

2012-02-22 11:59:43 (читать в оригинале)

Internet users in the UAE on the du network would face a possible downgrade of services following an undersea cable cut between Dubai and Oman. Telecom operator du confirmed the disruption in an email statement.

---

Dubai in Guinness for longest driverless metro

2012-02-22 11:53:21 (читать в оригинале)

The Dubai Metro, comprising red and green Lines, has entered the Guinness World Records as the longest driverless metro network in the world spanning 75km.

---

BMI: Middle East and Africa Pharma and Healthcare Insight (Mar-12)

2012-02-22 11:45:00 (читать в оригинале)

BMI View: The better-regulated markets of the Gulf Cooperation Council (GCC), South Africa and Israel will remain the most rewarding and least risky for drug makers operating in the Middle East and Africa (MEA). However, these markets are rapidly approaching maturity and are expected to grow only in the mid-to-high single digits. As pharmaceutical companies look to enter markets with higher potential, they should turn their attention first to the Gulf Levant and then North Africa, where population demographics, the regulatory framework and macroeconomic factors will facilitate growth.Sub-Saharan African (SSA) countries remain the final frontier in terms of investment because the risks in these countries are higher and at present the rewards are lower. However, their appeal lies in the long term and the companies that establish their brands sooner rather than later will benefit most. Generally speaking, BMI has preferred the Southern African region over East Africa, followed in preference by West and Central Africa. However, due to slightly improved conditions in Nigeria and a downgrade to Uganda?s Pharmaceuticals & Healthcare Risk/Reward Ratings (RRRs), which is the new term for BMI?s Business Environment Ratings (though the scoring methodology remains unchanged), we now regard the East and West and Central Africa as being of relatively similar attractiveness for multinational drug makers. We believe West and Central Africa has higher rewards and East Africa has fewer risks.However, Africa is not homogenous and there are exceptions within regions that stand out and deserve particular mention, such as Ghana, which we are bullish about, and Zimbabwe, about which we are less confident. BMI expects the countries that drug makers choose to enter will continue to be decided along ex-colonial lines, as language and contacts are often barriers to market entry. These barriers can be broken down by trade envoys, embassies and ambassadors that can facilitate business i